Dr. Chalmers has more than 30 years of pharmaceutical industry expertise with major multinational companies in pharmaceutical development, clinical research and regulatory affairs. A member of the Swiss Industrial Pharmacists Association, the Pharmaceutical Society of Basel, and the Royal Pharmaceutical Society of Great Britain, Dr. Chalmers is a frequent, invited speaker at international seminars on regulatory authorities, the quality of pharmaceuticals and international regulatory affairs.

“Our new Switzerland office continues the expansion of our European operation and builds upon the strength of our current activities,” said Sucampo Pharmaceuticals President and CEO Ryuji Ueno, M.D., Ph.D., Ph.D. “Having a strong presence throughout Europe is an important part of our global product development and marketing strategy. We are pleased to have Dr. Chalmers overseeing the work at our Oxford and Basel offices as we advance AMITIZA through the regulatory process in Europe and other overseas markets, where we have exclusive product commercialization rights. Consistent with our stated goals, we expect to begin submitting EU marketing authorization applications for AMITIZA for chronic idiopathic constipation in the first half of this year.”

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals has proven success in developing, commercializing and marketing drugs based on prostones. AMITIZA® (lubiprostone), the company’s U.S. approved and marketed drug for chronic idiopathic constipation, also is being developed for other gastrointestinal indications with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of innovative compounds with the potential to target underserved diseases affecting millions of patients worldwide. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.